CoChat

MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E

Open access
Trejo, Christy L., Juan, Joseph, Vicent, Silvestre, Sweet-Cordero, Alejandro, McMahon, Martin · 2012 · Cancer Research
Cited by 49

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Genetically engineered mouse (GEM) models of lung tumorigenesis allow careful evaluation of lung tumor initiation, progression, and response to therapy. Using GEM models of oncogene-induced lung cancer, we show the striking similarity of the earliest stages of tumorigenesis induced by KRASG12D or BRAFV600E. Cre-mediated expression of KRASG12D or BRAFV600E in the lung epithelium of adult mice initially elicited benign lung tumors comprising cuboidal epithelial cells expressing markers of alveolar pneumocytes. Strikingly, in a head-to-head comparison, oncogenic BRAFV600E elicited many more such benign tumors and did so more rapidly than KRASG12D. However, despite differences in the efficiency of benign tumor induction, only mice with lung epithelium expression of KRASG12D developed malignant non–small cell lung adenocarcinomas. Pharmacologic inhibition of mitogen-activated protein (MAP)–extracellular signal-regulated kinase (ERK) kinase (MEK)1/2 combined with in vivo imaging showed that initiation and maintenance of both BRAFV600E- or KRASG12D-induced lung tumors was dependent on MEK→ERK signaling. Although the tumors dramatically regressed in response to MEK1/2 inhibition, they regrew following cessation of drug treatment. Together, our findings show that RAF→MEK→ERK signaling is both necessary and sufficient for KRASG12D-induced benign lung tumorigenesis in GEM models. The data also emphasize the ability of KRASG12D to promote malignant lung cancer progression compared with oncogenic BRAFV600E. Cancer Res; 72(12); 3048–59. ©2012 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/0008-5472.can-11-3649

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 49

Metadata

Authors
Trejo, C. L., Juan, J., Vicent, S., Sweet-Cordero, A., & McMahon, M.
Venue
Cancer Research
Published
2012-06-14
Volume
72
Issue
12
Pages
3048-3059
ISSN
  • 0008-5472 (ISSN-L)
  • 1538-7445
OpenAlex
W2106493454
Cited by
49
References
4
FWCI
3.14
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E. https://app.cochat.ai/papers/10.1158/0008-5472.can-11-3649
The paper
Trejo, C. L., Juan, J., Vicent, S., Sweet-Cordero, A., & McMahon, M. (2012). MEK1/2 Inhibition Elicits Regression of Autochthonous Lung Tumors Induced by KRASG12D or BRAFV600E. Cancer Research. https://doi.org/10.1158/0008-5472.can-11-3649

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.